drugset / Trial / NCT01794780

A 1-year Multi-center, Prospective, Cohort Study in Patients With Chronic Obstructive Pulmonary Disease Treated With Long-acting Bronchodilator

NCT01794780

Phase 4 Completed 2229 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This multi-center study is designed to describe natural history of disease, treatment and health care products in physician-diagnosed COPD patients who require adding daily maintenance therapy in real world. The study planned to enroll 550 patients in Indacaterol group and 9450 patients in non- Indacaterol group, a total of 10,000 patients. Enrollment was stopped at 2253 patients due to low recruitment in indacaterol group. Finally a total of 2229 patients were analyzed in full analysis set. A total of 2253 patients entered into the database, of which 24 patients were exclude during the data review meetings, because they did not met the inclusion/exclusion criteria. Hence a total of 2229 patients enrolled successfully.

Timeline

Start
2013-02-05
Primary completion
2015-05-25
Completion
2015-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Budesonide Small molecule 160 ug
Subject Fluticasone Other / unclassified 250 ug
Subject Fluticasone Other / unclassified 500 ug
Subject Formoterol Other / unclassified 4.5 ug
Subject Indacaterol Other / unclassified 150 ug
Subject Salmeterol Other / unclassified 50 ug
Subject Theophylline Small molecule
Subject Tiotropium Other / unclassified 18 ug